Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 3/20 | 0.52 |
| ▸ | CD44 | P16070 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 5/20 | 0.41 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.37 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30331914 | 1.00 | PNMT (0.52) | PNMTCD44MAOBPOLBSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2378664 | 0.98 | PNMT (0.50) | PNMTCD44MAOBPOLBSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6607726 | 0.98 | PNMT (0.50) | PNMTCD44MAOBPOLBSMN1; SMN2 | |
| SCHEMBL18743002 | 0.89 | CD44 (0.44) | PNMTCD44MAOBPOLBSMN1; SMN2 | |
| SCHEMBL15943597 | 0.87 | CD44 (0.42) | PNMTCD44MAOBPOLBSMN1; SMN2 | |
| SCHEMBL1041309 | 0.86 | HTR2C (0.54) | PNMTCD44MAOBPOLBSMN1; SMN2 | |
| SCHEMBL588622 | 0.84 | PNMT (0.52) | PNMTCD44MAOBPOLBSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL15410642 | 0.82 | PNMT (0.50) | PNMTCD44MAOBPOLBSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL12985101 | 0.82 | PNMT (0.50) | PNMTCD44MAOBPOLBSMN1; SMN2 | |
| 6,7-Dihydro-5H-Pyrrolo[3,4-B]Pyridine SCHEMBL103669 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 753 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109702-A1 | NOVEL GSPT PROTEIN DEGRADER AND APPLICATION THEREOF | GENOSCO INC (US) | 2026-04-23 | — | — | US | claimed |
| CN-111655695-B | Substituted furopyrimidine compounds as PDE1 inhibitors | 达特神经科学有限公司 | 2025-05-27 | — | — | CN | claimed |
| WO-2024148210-A1 | CYCLIN-DEPENDENT KINASE 12 MODULATORS AND THERAPEUTIC USES THEREOF | ALLIANTHERA (SUZHOU) BIOPHARMACEUTICAL CO., LTD. (CN) | 2024-07-11 | — | — | WO | claimed |
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | claimed |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | claimed |
| US-20220289753-A1 | SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2022-09-15 | — | — | US | claimed |
| EP-4010335-A1 | SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2022-06-15 | — | — | EP | claimed |
| EP-3894401-A2 | NAPHTHYRIDINE AND QUINOLINE DERIVATIVES USEFUL AS ALK5 INHIBITORS | Theravance Biopharma R&D IP, LLC (US) | 2021-10-20 | — | — | EP | claimed |
| US-20210244717-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2021-08-12 | — | — | US | claimed |
| CN-113195467-A | Naphthyridine and quinoline derivatives useful as ALK5 inhibitors | 施万生物制药研发IP有限责任公司 | 2021-07-30 | — | — | CN | claimed |
| EP-2611804-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Forma TM, LLC. (US) | 2013-07-10 | — | — | EP | claimed |
| WO-2012031196-A9 | 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL] AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | FORMA TM, LLC (US) | 2013-06-13 | — | — | WO | claimed |
| WO-2012031197-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | claimed |
| WO-2012031196-A1 | 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL] AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | claimed |
| EP-0997462-B1 | NOVEL NAPHTHYRIDINE DERIVATIVES OR SALTS THEREOF | NIPPON KAYAKU KK (JP) | 2004-12-22 | — | — | EP | claimed |
| US-6294547-B1 | Naphthyridine deratives or salts thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2001-09-25 | — | — | US | claimed |
| EP-0997462-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES OR SALTS THEREOF | Nippon Kayaku Kabushiki Kaisha (JP) | 2000-05-03 | — | — | EP | claimed |
| EP-0588500-B1 | 3-Oxadiazolyl-1,6-naphthyridine derivatives with affinity for benzodiazepine receptors | DAINIPPON PHARMACEUTICAL CO (JP) | 1998-11-04 | — | — | EP | claimed |
| US-5424433-A | Benzodiazepine receptor agonist | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1995-06-13 | — | — | US | claimed |
| EP-0588500-A2 | 3-Oxadiazolyl-1,6-naphthyridine derivatives with affinity for benzodiazepine receptors | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1994-03-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109702-A1 | NOVEL GSPT PROTEIN DEGRADER AND APPLICATION THEREOF | CRBN, PSMB3, PSMB1 | PNMT 4302/4885CD44 3336/4885MAOB 2732/4885 |
| US-20220289753-A1 | SHP2 INHIBITORS | PTPN1, PTPN2, PTPN7 | PNMT 4815/4885CD44 1736/4885MAOB 4682/4885 |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | PNMT 132/4885CD44 4326/4885MAOB 99/4885 |
| US-11730720-B2 | ALK5 inhibitors | ALK, ACVR1, ACVRL1 | PNMT 4044/4885CD44 4024/4885MAOB 3002/4885 |
| US-20210244717-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | PNMT 222/4885CD44 4182/4885MAOB 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.